Magnesium in biology be used as adjuvant therapy in patients on optimal treatment for severe congestive heart failure, increasing survival rate and improving clinical symptoms and patient's quality of life. Magnesium can affect muscle relaxation through direct action on cell membranes. Mg ions close certain types of calcium channels, which conduct positively charged calcium ions into neurons. With an excess of magnesium, more channels will be blocked and nerve cells activity will decrease. Intravenous magnesium sulphate is used in treating pre-eclampsia. For other than pregnancy-related hypertension, a meta-analysis of 22 clinical trials with dose ranges of 120 to 973 mg/day and a mean
Magnesium hydroxide in 1872 for a suspension of magnesium hydroxide formulated at about 8%w/v. It was sold under the brand name "Phillips' Milk of Magnesia" for medicinal usage. Although the name may at some point have been owned by GlaxoSmithKline, USPTO registrations show "Milk of Magnesia" and "Phillips' Milk of Magnesia" have both been assigned to Bayer since 1995. In the UK, the non-brand (generic) name of "Milk of Magnesia" and "Phillips' Milk of Magnesia" is "Cream of Magnesia" (Magnesium Hydroxide Mixture, BP). It is added directly to human food, and is affirmed as generally recognized as safe by the FDA. It